Tang A, Zak S, Iorio R, et al. - This research was sought to ascertain if a protocol of 81mg aspirin (ASA) bis in die (BID) is safe and/or effective in preventing venous thromboembolism (VTE) in patients undergoing revision total hip arthroplasty (rTHA) vs 325mg ASA BID. Initially, 325mg ASA BID was given to the patients, but switched to 81mg ASA BID. Between 2011 and 2019, researchers conducted a retrospective review to distinguish 1,361 consecutive rTHA patients and their associated 90-day post-operative complications such as VTE, including pulmonary embolism (PE) and/or deep venous thrombosis, as the primary outcome; and gastrointestinal and wound bleeding, acute peri-prosthetic joint infection, and mortality as the secondary outcome.The results of this study reveal that applying a protocol of 81mg of ASA BID is non-inferior to 325mg ASA BID and for maintaining low rates of VTE, it can be safe and effective in patients undergoing rTHA.